Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 145,445 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder Clear all
Completed Not applicable Interventional Results available

Anxiety in Older Veterans

NCT02400723
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Progressive Muscle Relaxation, Diaphragmatic Breathing, Psychoeducation (Placebo)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Nov 11, 2026, 10:32 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels

NCT03747523
View directory record Official record
Conditions
Ergocalciferol
Interventions
Ergocalciferol
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 4 Interventional Results available

Management of Sub-Clinical Bacteriuria in Pregnancy

NCT03275623
View directory record Official record
Conditions
Cystitis, Cystitis;Puerperium, Pyelonephritis
Interventions
Antibiotic, Standard Prenatal Care
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 4 Interventional Results available

Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

NCT01395823
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ergocalciferol supplementation, placebo
Dietary Supplement · Other
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Redding, California • Albany, Georgia • Shreveport, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Nov 11, 2026, 10:32 PM EST
Active, not recruiting Phase 2 Interventional

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02703623
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Apalutamide, Cabazitaxel, Carboplatin, Ipilimumab, Laboratory Biomarker Analysis, Prednisone
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 11, 2026, 10:32 PM EST
Recruiting Phase 1Phase 2 Interventional

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

NCT06364423
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Leukemia, Acute Lymphoblastic, Small Lymphocytic Lymphoma
Interventions
Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine, Rituximab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 11, 2026, 10:32 PM EST
Completed Not applicable Interventional Results available

A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients

NCT05349123
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Mindful Breathing, Home-Based Pulmonary Rehabilitation
Behavioral
Lead sponsor
Minnesota HealthSolutions
Industry
Eligibility
40 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Nov 11, 2026, 10:32 PM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

NCT06411223
View directory record Official record
Conditions
Hiv
Interventions
Collaborative drug therapy management model, Cabotegravir/Rilpivirine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

NCT00104923
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
fenretinide
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Nov 11, 2026, 10:32 PM EST
Completed No phase listed Observational

The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment

NCT06096623
View directory record Official record
Conditions
Cancer, Breast Cancer, Colorectal Cancer
Interventions
Weekly Survey
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Safety/Immunogenicity Hantaan Virus DNA Vaccine and Puumala Virus DNA Vaccine, For Prevention of HFRS

NCT04333459
View directory record Official record
Conditions
Hantaan Virus Nephropathy, Puumala Virus Nephropathy
Interventions
Hantaan DNA Vaccine/Puumala DNA Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 11, 2026, 10:32 PM EST
Completed No phase listed Observational

Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study

NCT00341159
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
35 Years to 64 Years
Enrollment
9,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 11, 2026, 10:32 PM EST
Terminated Phase 1 Interventional

FAAH Inhibitor Trial for Adults With Tourette Syndrome

NCT02134080
View directory record Official record
Conditions
Tourette Syndrome
Interventions
PF-04457845, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Nov 11, 2026, 10:32 PM EST
Completed Early Phase 1 Interventional Results available

18F-DCFBC PET/CT in Prostate Cancer

NCT02190279
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 2 Interventional Results available

Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

NCT01442779
View directory record Official record
Conditions
Respiratory Tract Diseases, Lung Diseases, Lung Diseases, Interstitial, Pulmonary Fibrosis
Interventions
Interferon alpha oral lozenge
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 1Phase 2 Interventional Results available

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

NCT01263379
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Nov 11, 2026, 10:32 PM EST
Withdrawn Phase 1 Interventional

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

NCT02658396
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Interventions
GO-203-2C, Bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 1Phase 2 Interventional

Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

NCT00136396
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 2 Interventional Results available

Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer

NCT01722162
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Bevacizumab, Capecitabine, Levocetirizine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Nov 11, 2026, 10:32 PM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease

NCT05477862
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Clinically Designed Improvisatory Music
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
55 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 11, 2026, 10:32 PM EST
Withdrawn Phase 1 Interventional

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

NCT05171062
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
bexmarilimab (FP-1305), Pembrolizumab
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Nov 11, 2026, 10:32 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

The Impact of Glomerular Disorders on Bone Quality and Strength

NCT04528446
View directory record Official record
Conditions
Glomerular Disease, Bone Diseases, Metabolic, Bone Fracture
Interventions
Dual-energy X-ray absorptiometry, High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT), Blood draw and Urine collection, Questionnaires
Radiation · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Nov 11, 2026, 10:32 PM EST
Withdrawn Not applicable Interventional

Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease

NCT01453803
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Harvesting and Implantation of Adipose-Derived Stem Cells
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Nov 11, 2026, 10:32 PM EST
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00030303
View directory record Official record
Conditions
Leukemia
Interventions
recombinant 70-kD heat-shock protein
Biological
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Nov 11, 2026, 10:32 PM EST